Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796 - Wikidata - wikimedia - TriplyDB

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

http://www.wikidata.org/entity/Q27486816

about

Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796 Impaired Replication of Hepatitis C Virus Containing Mutations in a Conserved NS5B Retinoblastoma Protein-Binding Motif Slow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C Virus Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women 1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus Preclinical Characterization of JTK-853, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase Mechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase.Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.The hepatitis C virus core protein can modulate RNA-dependent RNA synthesis by the 2a polymerase.Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661.Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.Compensatory mutations restore the replication defects caused by cytotoxic T lymphocyte escape mutations in hepatitis C virus polymerase.In vitro characterization of the activity of PF-05095808, a novel biological agent for hepatitis C virus therapy.Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection.Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase.Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.Antiviral therapy for hepatitis C virus: beyond the standard of care.Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research.New horizons in hepatitis C antiviral therapy with direct-acting antivirals.The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.The juxtamembrane sequence of the Hepatitis C virus polymerase can affect RNA synthesis and inhibition by allosteric polymerase inhibitors.Polymerases of paramyxoviruses and pneumoviruses.Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.

P2860

Q26783056-0F758136-3C09-4FE3-AFCB-856764EF3D3E Q27487769-69EEEB9A-D371-467A-82DA-57953C0959B9 Q27488386-4802D201-E32F-4E34-865C-5D639E083F51 Q27488885-9ECC05E4-80D2-431A-887E-C4370F9369EC Q27488887-233404EF-7A8C-41AA-9A04-0702F1DD4764 Q27490222-BB446ABD-C89A-4584-93F6-5DFA718656BC Q27490956-99BCD92E-FD47-49ED-9125-EDFBAC3A7BF0 Q27679235-39DE214F-527A-42E3-B1C1-730AB05CDFAA Q30318760-4A082550-076E-4F76-9E05-46E73241FF1D Q32183060-C4DB76E9-DBBC-4292-B867-B53152A65172 Q33798031-784C4489-058D-4B41-B993-9306D3EEE892 Q33934312-70498E7F-7B25-40D7-AF0B-B76E38AC5ED9 Q34276394-65C16A5E-4EAD-476C-883E-E4D4F0785729 Q34409020-3247FE6C-68E4-465B-9831-A50089DEBEB2 Q34489239-EE2FB453-D4EF-4A54-8E0F-86FC4148BD62 Q34518202-A8B81294-CE55-4C54-9C4D-2F9D955EAEE7 Q35004972-59BFCCCC-5606-4E4B-9FD1-6509C3639208 Q35064369-BE46AECB-ACBF-49F7-9770-FC6AF5D148B8 Q35103718-4FA56CC4-E9CE-402A-83F2-93470A5C2CA7 Q35116027-905AE458-5C8B-4891-BB0F-C341A33EEDC7 Q35260330-0A632EEB-4B7A-472C-8522-FF09AC491C0F Q35531173-26608825-F2BC-464A-A951-156BF9C5817F Q35806350-11DFBA39-E3C8-4925-A40C-84CB9A40E540 Q35935502-D90EDD62-9D17-4F33-813B-6F485AD29544 Q37263558-E4FF7B6E-ADB0-4B7A-9305-00F57CD603A8 Q37481292-B83F34D5-73FA-494E-B810-AB99568565AA Q37618717-2AFF7A90-36C4-4A1B-AEA7-67D8BA4E2464 Q37855859-E140D662-54A5-4324-A448-87DE152C2976 Q37945201-7A484E49-1BE3-46A3-A459-8D00C0B33961 Q38034733-B592D1FF-7FAA-4247-B497-CE6F3AD1AD89 Q38087250-5C358182-0D23-427E-AEC1-2C84AB3F7EBA Q38113079-4B95EE62-2325-43DA-A439-A814B36D885C Q38283239-38266002-F2F4-4BBE-AF69-2CE002A8EA0D Q38844822-05104121-304C-4A84-90FF-EBD49B58B1DE Q38864459-BB9A8711-8281-40CC-860D-BD17FFDE55C8 Q38884375-1864D5ED-E192-449A-9985-680CB62524B0 Q39011481-D05C2EC0-1EC2-4A68-99EE-5BCA9E72B6D8 Q39157657-4842495F-4F9C-4650-B0DF-A93AA74AD200 Q39376758-B5E1EB1D-287D-49CD-9F12-75FBB59DB3FB Q39518505-CFAA5D37-EBF7-4CBF-A0F0-6123A45412AF

P2860

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

http://www.wikidata.org/entity/Q27486816

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Molecular Mechanism of Hepatit ...... Benzofuran Inhibitor, HCV-796

@ast

Molecular Mechanism of Hepatit ...... Benzofuran Inhibitor, HCV-796

@en

Molecular Mechanism of Hepatit ...... Benzofuran Inhibitor, HCV-796

@nl

type

label

Molecular Mechanism of Hepatit ...... Benzofuran Inhibitor, HCV-796

@ast

Molecular Mechanism of Hepatit ...... Benzofuran Inhibitor, HCV-796

@en

Molecular Mechanism of Hepatit ...... Benzofuran Inhibitor, HCV-796

@nl

prefLabel

Molecular Mechanism of Hepatit ...... Benzofuran Inhibitor, HCV-796

@ast

Molecular Mechanism of Hepatit ...... Benzofuran Inhibitor, HCV-796

@en

Molecular Mechanism of Hepatit ...... Benzofuran Inhibitor, HCV-796

@nl

P1433

Q27486816-6ED79415-E1E0-4790-8268-4BCA3BC488C7

P1476

Q27486816-E5A66C14-65CB-4D15-A085-61B18F86B84F

P2093

Q27486816-0880CF0B-12B4-4E17-9144-34BE8F73DBF8

Q27486816-13B049B9-5274-4B9C-B27D-809D8733CEEA

Q27486816-3377DF3E-0B7A-48FC-8546-BB5D8BB9C759

Q27486816-47ECC1D7-B6F1-474A-A73E-DF536C80C95C

Q27486816-4B0BB294-AD95-47AE-968B-B46CF36AEA30

Q27486816-57EA84C1-C04C-4A45-889E-858D389AA9CC

Q27486816-6F88821D-C9CF-4653-A588-37D111590E49

Q27486816-747AE65C-AECE-4DC5-AC55-7DD78A5F185A

Q27486816-97BFD6DA-3FF8-48BC-A8F0-8CA782718305

Q27486816-AA43791E-14B0-43D9-A840-31F00437071E

P2860

Q27486816-008F5194-0B1E-47E0-B904-18F5C03202D3

Q27486816-03C095BA-6B26-40C5-AF40-5212115E8991

Q27486816-04B54716-97A0-4799-B4FF-3FE64D83D8B9

Q27486816-05563F2A-28EF-45A5-8B5A-4B7DF615B0FA

Q27486816-0866BB62-5208-4D9D-9D26-9146F92BF938

Q27486816-0B444DFA-81AB-4131-A7BF-A2CC8FF8908B

Q27486816-0DEC199D-39D6-41C7-A985-0D630B3CA741

Q27486816-1A1DA6F2-BBD2-4BDF-80E3-20FAA3E88594

Q27486816-246C165B-0253-4A81-BA2A-96DA1B568C61

Q27486816-28F38C92-0AC9-4984-8394-690EAC061CD4

P304

Q27486816-90633131-BC43-4103-A635-CCD455F921CA

P31

Q27486816-B7649A84-DEAB-4BEF-822C-D08FACBC7B4A

P356

Q27486816-F3540F3E-38EF-48D7-8B32-A912899EA459

P407

Q27486816-4326B625-BD63-4BDB-B559-BE3F0391CEE5

P433

Q27486816-E23188BC-7857-417B-B6BA-375E7238DEDC

P478

Q27486816-CD4D55B3-69A2-4EBA-B28C-A44503548E5A

P577

Q27486816-65B8EE4A-42E6-4F35-A753-6890C0E7F14C

P5875

Q27486816-CF98233F-FCEE-48C7-8A84-6130C324693D

P698

Q27486816-7FC9A4B2-CEF3-49E7-8455-97CF57E45EDA

P932

Q27486816-116F7409-CCBC-42F6-8FFB-88CAB7CA5E0C

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Molecular Mechanism of Hepatit ...... Benzofuran Inhibitor, HCV-796

@en

P2093

Anita Y M Howe

http://www.w3.org/2001/XMLSchema#string

Dorothy C Young

http://www.w3.org/2001/XMLSchema#string

Girija Krishnamurthy

http://www.w3.org/2001/XMLSchema#string

Huiming Cheng

http://www.w3.org/2001/XMLSchema#string

Joel Bard

http://www.w3.org/2001/XMLSchema#string

John O'Connell

http://www.w3.org/2001/XMLSchema#string

Rajiv Chopra

http://www.w3.org/2001/XMLSchema#string

Srinivas K Chunduru

http://www.w3.org/2001/XMLSchema#string

Stanley Mullen

http://www.w3.org/2001/XMLSchema#string

Stephen Johann

http://www.w3.org/2001/XMLSchema#string

P2860

Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver

Robust hepatitis C virus infection in vitro.

Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.

Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture

Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme

Molecular Mechanism of a Thumb Domain Hepatitis C Virus Nonnucleoside RNA-Dependent RNA Polymerase Inhibitor

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759

P304

3327-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00238-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5296383

http://www.w3.org/2001/XMLSchema#string

P698

18559648

http://www.w3.org/2001/XMLSchema#string

P932

2533464

http://www.w3.org/2001/XMLSchema#string